When Ms. RS came into my clinic for a new patient evaluation, she was suffering from highly active skin disease, joint swelling, pain and poor mobility. Her body mass index was 46, indicating class III obesity. A treatment plan focused solely on her inflammatory disease without addressing her weight would not fully address her overall disease burden.

Annals of Internal Medicine has published the updated 2025 U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guidelines on adult Overweight and Obesity management. Here is a review of the guidelines, including five key takeaways for rheumatologists.

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com.

Therapeutic advances have transformed the prognosis of many rheumatic diseases, allowing patients to achieve sustained disease control and avoid irreversible organ damage. For some, however, rheumatology conditions progressively cause decline, damage, loss of function, and ultimately shortened life expectancy. Palliative care is an under-utilized and often misunderstood tool within rheumatology.

Gabapentin use jumped quickly in Michigan after the drug was removed from the state's controlled substance schedule in 2024, a cross-sectional study showed.